Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to broaden its capacity.
Valued at more than $3bn, the partnership is set to almost double Regeneron’s manufacturing capacity in the US by using Fujifilm’s new biopharmaceutical facility in Holly Springs, North Carolina.
Go deeper with GlobalData
The agreement will facilitate additional manufacturing of Regeneron’s biologic medicines. The technology transfer is set to begin immediately.
According to the agreement, Fujifilm will support Regeneron’s US-based manufacturing for more than a decade.
This is facilitated through existing and planned expansions at Fujifilm’s Holly Springs site, which is expected to commence operations later this year.
The site is a key part of Fujifilm’s kojoX interconnected manufacturing network, which offers a modular approach with equipment and processes to enhance supply chain security and technology transfers.
Regeneron’s focus on innovation and patient care is further evidenced by its substantial investments in New York State.
It is currently expanding its Tarrytown campus with an investment of nearly $3.6bn, which is said to generate 1,000 full-time jobs and extend its research and preclinical manufacturing offerings.
Additionally, a new fill/finish manufacturing facility is under construction in Rensselaer, New York, and the acquisition of a property in Saratoga Springs is set to support production and potentially increase manufacturing capacity.
Regeneron board co-chair, CEO and president Leonard Schleifer said: “Our innovative approach has filled our commercial and clinical pipeline with important new medicines and driven a need for even more manufacturing capacity to fulfil the promise of our science.
“We are meeting this need through increased investment in New York and North Carolina. We are proud to advance biotech innovation, which directly improves the health of people around the globe, while generating economic growth and high-paying jobs for America itself.”
Regeneron noted that its current and planned investments in infrastructure and manufacturing across New York and North Carolina are projected to exceed $7bn.
